TY  - JOUR
AU  - Barbour, Andrew B
AU  - Kirste, Simon
AU  - Grosu, Anca-Liga
AU  - Siva, Shankar
AU  - Louie, Alexander V
AU  - Onishi, Hiroshi
AU  - Swaminath, Anand
AU  - Teh, Bin S
AU  - Psutka, Sarah P
AU  - Weg, Emily S
AU  - Chen, Jonathan J
AU  - Zeng, Jing
AU  - Gore, John L
AU  - Hall, Evan
AU  - Liao, Jay J
AU  - Correa, Rohann J M
AU  - Lo, Simon S
TI  - The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma.
JO  - Cancers
VL  - 15
IS  - 14
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2023-01542
SP  - 3672
PY  - 2023
AB  - Localized renal cell carcinoma is primarily managed surgically, but this disease commonly presents in highly comorbid patients who are poor operative candidates. Less invasive techniques, such as cryoablation and radiofrequency ablation, are effective, but require percutaneous or laparoscopic access, while generally being limited to cT1a tumors without proximity to the renal pelvis or ureter. Active surveillance is another management option for small renal masses, but many patients desire treatment or are poor candidates for active surveillance. For poor surgical candidates, a growing body of evidence supports stereotactic ablative radiotherapy (SABR) as a safe and effective non-invasive treatment modality. For example, a recent multi-institution individual patient data meta-analysis of 190 patients managed with SABR estimated a 5.5
KW  - RCC (Other)
KW  - SABR (Other)
KW  - SBRT (Other)
KW  - kidney cancer (Other)
KW  - radiation oncology (Other)
KW  - renal cancer (Other)
KW  - renal carcinoma (Other)
KW  - stereotactic body radiation therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37509333
C2  - pmc:PMC10377531
DO  - DOI:10.3390/cancers15143672
UR  - https://inrepo02.dkfz.de/record/277874
ER  -